LYEL

Lyell Immunopharma, Inc.

$14.04 -0.01 (-0.07%) At close · Jul 6

Market Cap

$327.61M

23,334,087

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-06-25	Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference	Conference
2026-06-12	Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress	Event
2026-06-08	Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion	Event
2026-06-04	Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress	Event
2026-06-01	Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026	Conference
2026-05-12	Lyell Immunopharma Announces Participation in May Investor Conferences	Conference
2026-05-06	Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026	Event
2026-04-07	Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference	Conference
2026-03-12	Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results	Event
2026-03-09	Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer	Event
2026-02-23	Lyell Immunopharma Announces Participation in March Investor Conferences	Conference

Source: https://ir.lyell.com/

Key facts CIK 1806952 CUSIP 55083R203 13F (30d) 1 filings 1 filers Visit website Investor relations